Visceral leishmaniasis: a trip to the Greek Islands is not always idyllic.
Although cutaneous leishmaniasis is occasionally seen in Australia in overseas travellers and migrants, visceral leishmaniasis has been reported rarely and only in people who were immunocompromised. We describe an 18-year-old immunocompetent man who presented with pancytopenia and a 2-week history of fever and lethargy a year after visiting the Greek Islands. Visceral leishmaniasis was diagnosed after a bone marrow biopsy showed protozoa, and the patient responded well to treatment with liposomal amphotericin. To our knowledge, this is the first case of visceral leishmaniasis in an immunocompetent patient in Australia.
Ju
Oui
O
Infectious Diseases, Queen Elizabeth Hospital, Woodville Road, Woodville, SA 5111, Australia. Oui.Ju@fmc.sa.gov.au
Grove
David I
DI
Jaksic
Wilfrid J
WJ
Dart
Geoffrey W
GW
D000293:Adolescent; D000666:Amphotericin B / Q000627:therapeutic use; D000818:Animals; D000900:Anti-Bacterial Agents / Q000627:therapeutic use; D000981:Antiprotozoal Agents / Q000627:therapeutic use; D001853:Bone Marrow / Q000469:parasitology*; D003937:Diagnosis, Differential; D006115:Greece; D006801:Humans; D007893:Leishmania donovani / Q000302:isolation & purification*; D007898:Leishmaniasis, Visceral / Q000150:complications / Q000175:diagnosis* / Q000188:drug therapy / Q000469:parasitology*; D008297:Male; D010198:Pancytopenia / Q000175:diagnosis / Q000209:etiology; D010322:Parvoviridae Infections / Q000175:diagnosis; D014195:Travel; D016896:Treatment Outcome
D000900:Anti-Bacterial Agents; D000981:Antiprotozoal Agents; D000666:Amphotericin B